FINWIRES · TerminalLIVE
FINWIRES

Nayax Growth Outlook Improves on Market Share Gains, Oppenheimer Says

By

Nayax (NYAX) is expected to benefit from higher cashless payment volume, more market share gains, recurring revenue growth, EV charging demand and better profit margins, Oppenheimer said in a note Wednesday.

The investment firm said Nayax could deliver a 41% adjusted earnings before interest, taxes, depreciation, and amortization compound annual growth rate through 2027 as it expands across vending, ticketing, EV charging, amusement, laundromats and parking.

Oppenheimer raised its revenue view to $515 million for this year and $633 million for 2027, while lifting its 2027 adjusted EBITDA estimate by about $10 million to $122 million.

Global unattended cashless payment volume could grow 19% annually from 2025 to 2029, reaching $257 billion, while Nayax should continue adding share, and Oppenheimer said it expects payments revenue to grow about 30% annually through 2028, while software revenue could rise about 20% a year on higher machine share and better average revenue per user.

Oppenheimer upgraded Nayax (NYAX) to outperform from perform and set an $86 price target, saying that Nayax's valuation is high, but long-term upside remains possible because of strong demand trends, recurring revenue, scale benefits and a business model that can hold up during weaker economic periods.

Shares of Nayax were up about 5.8% in recent trading.

Price: $74.81, Change: $+4.13, Percent Change: +5.84%

Related Articles

Wire

Ooma Fiscal Q1 Adjusted Earnings, Revenue Rise; Shares Gain After Hours

Ooma (OOMA) reported fiscal Q1 adjusted earnings late Tuesday of $0.35 per diluted share, up from $0.20 a year earlier.Analysts polled by FactSet expected $0.32.Revenue in the three months ended April 30 rose to $81.1 million from $65 million a year earlier.Analysts surveyed by FactSet expected $79.8 million.Ooma expects fiscal Q2 adjusted EPS of $0.33 to $0.34 on revenue of $81.6 million to $82.3 million.Analysts polled by FactSet expect EPS of $0.31 on revenue of $80.2 million.The company boosted fiscal 2027 adjusted EPS guidance to $1.29 to $1.34 on revenue of $326 million to $328.5 million. Prior guidance was EPS of $1.26 to $1.31 on revenue of $321 million to $325 million.Analysts surveyed by FactSet expect EPS of $1.29 on revenue of $322.8 million.Ooma shares rose 4.8% in after-hours trading.

$OOMA
Wire

Jade Biosciences Says First Participant Dosed in First-in-Human Phase 1 Trial of JADE201

Jade Biosciences (JBIO) said late Tuesday the first participant has been dosed in a first-in-human phase 1 clinical trial of JADE201, an investigational, half-life extended, afucosylated monoclonal antibody.The first-in-human trial is a placebo-controlled study assessing single ascending doses of JADE201 in participants with rheumatoid arthritis, according to a statement.Jade said interim phase 1 data in rheumatoid arthritis anticipated in 2027 are expected to inform indication prioritization across potential autoimmune indications supported by B cell activating factor receptor biology.

$JBIO
Wire

Zscaler Fiscal Q3 Adjusted Earnings, Revenue Rise; Q4 Guidance Set

Zscaler (ZS) reported fiscal Q3 adjusted earnings late Tuesday of $1.08 per diluted share, up from $0.84 a year earlier.Analysts polled by FactSet expected $1.01.Revenue for the three months ended April 30 was $850.5 million, up from $678 million a year earlier.Analysts surveyed by FactSet expected $835.6 million.For fiscal Q4, the company expects adjusted EPS of $1.08 to $1.09 on revenue of $875 million to $878 million. Analysts expect EPS of $1.03 on revenue of $878.6 million.For the full-year fiscal 2026, the company now expects adjusted EPS of $4.10 to $4.11 on revenue of $3.329 billion to $3.332 billion. It earlier expected adjusted EPS of $3.99 to $4.02 on revenue of $3.31 billion to $3.32 billion.Analysts expect EPS of $4.01 on revenue of $3.32 billion.

$ZS